Drug Trial Radar · NCT04307186
Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
Last checked: Nov 19, 2026Latest source record: Nov 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
57
Actual
Start
Nov 18, 2020
Primary completion
Sep 5, 2022
Study completion Sep 6, 2022
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Mar 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers in this study want to find the appropriate dose of drug BAY1747846 for adults undergoing MRI for known or highly suspected brain and/or spinal cord conditions so that the image quality is similar to that of drug gadobutrol for adults undergoing MRI. MRI stands for Magnetic resonance imaging which produces body pictures created by using magnetic energy rather than x-ray energy. Both BAY1747846 and gadobutrol are medicinal products known as gadolinium-based contrast agents (GBCA) which are used in MRI examinations to provide contrast enhancement and improve imaging performance. Gadobutrol (brand name: Gadavist, Gadovist) has been approved worldwide for the diagnosis of various disorders in adult and pediatric patients. BAY1747846 is a new GBCA under development with the goal to provide similar imaging performances in MRI. Participants in this study will receive both BAY1747846 and gadobutrol with a period of 3 - 14 days in between. A MRI examination will be performed after each injection. Participant will stay in this study for 2 - 4 weeks depending on the scheduling of the visits.
Conditions
- Central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846)Drug
Solution for IV injection, single dose
Gadobutrol (Gadovist/Gadavist)Drug
Solution for IV injection, single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Diagnostic PreferenceTime frame: At 5 minute post each injection
Locations
17 sites in 4 countries. Site status is shown where the registry gives one.
Northwestern University
Chicago, Illinois
University of Iowa Hospitals & Clinics
Iowa City, Iowa
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania
UMHAT Sveti Georgi
Plovdiv, Bulgaria
Acibadem City Clinic Multiprofile Hospital for Active Treatm
Sofia, Bulgaria
University Multiprofile Hosp. for Active Treat. Sveti Ivan
Sofia, Bulgaria
MVZ Prof. Uhlenbrock und Partner
Dortmund, North Rhine-Westphalia, Germany
Universitätsklinikum Essen
Essen, North Rhine-Westphalia, Germany
Friedrich-Schiller-Uni. Jena
Jena, Thuringia, Germany
National Hospital Organization Kyushu Medical Center
Fukuoka, Japan
Social Medical Corporation the Chiyukai foundation Fukuoka Wajiro Hospital
Fukuoka, Japan
Hiroshima City Hiroshima Citizens Hospital
Hiroshima, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
National Hospital Organization Himeji Medical Center
Himeji, Hyōgo, Japan
Hyogo Prefectural Nishinomiya Hospital
Nishinomiya, Hyōgo, Japan
Kishiwada Tokushukai Hospital
Kishiwada, Osaka, Japan
National Hospital Organization Kanmon Medical Center
Shimonoseki, Yamaguchi, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.